Gentian Diagnostics AS (OSTO:GENTOO) Beneish M-Score: -3.07 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GENTOO Gentian Diagnostics AS OSTO:GENTOO
60 GF Score
Price kr40.00
GF Value kr53.59
Valuation Modestly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Beneish M-Score?

Gentian Diagnostics AS OSTO:GENTOO 60 Beneish M-Score is -3.07 as of Aug. 17, 2026. GuruFocus rates OSTO:GENTOO with a GF Score™ of 60/100 and a GF Value™ of kr53.59 (Modestly Undervalued). Among 767 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks better than 80.05% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.07 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Gentian Diagnostics AS's Beneish M-Score or its related term are showing as below:

OSTO:GENTOo' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61   Med: -2.57   Max: -0.1
Current: -3.07

During the past 13 years, the highest Beneish M-Score of Gentian Diagnostics AS was -0.10. The lowest was -3.61. And the median was -2.57.


Gentian Diagnostics AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Beneish M-Score Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.55 -2.73 -3.26 -0.74 -3.31

Gentian Diagnostics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -0.10 -3.31 -3.26 -3.07

OSTO:GENTOO vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Beneish M-Score falls into.


OSTO:GENTOO
60GF Score
Gentian Diagnostics AS OSTO:GENTOO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Gentian Diagnostics AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1465+0.528 * 0.9762+0.404 * 0.4394+0.892 * 1.1147+0.115 * 1.5898
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9449+4.679 * -0.123879-0.327 * 1.2505
=-3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was kr45.4 Mil.
Revenue was 49.768 + 43.921 + 46.591 + 41.836 = kr182.1 Mil.
Gross Profit was 27.552 + 23.064 + 27.038 + 23.441 = kr101.1 Mil.
Total Current Assets was kr178.2 Mil.
Total Assets was kr223.5 Mil.
Property, Plant and Equipment(Net PPE) was kr22.9 Mil.
Depreciation, Depletion and Amortization(DDA) was kr9.0 Mil.
Selling, General, & Admin. Expense(SGA) was kr53.6 Mil.
Total Current Liabilities was kr24.0 Mil.
Long-Term Debt & Capital Lease Obligation was kr16.8 Mil.
Net Income was 4.421 + -20.294 + 3.468 + 3.998 = kr-8.4 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0.0 Mil.
Cash Flow from Operations was -3.22 + -12.57 + 26.131 + 8.938 = kr19.3 Mil.
Total Receivables was kr35.5 Mil.
Revenue was 43.57 + 44.501 + 42.61 + 32.699 = kr163.4 Mil.
Gross Profit was 19.344 + 28.376 + 23.831 + 16.984 = kr88.5 Mil.
Total Current Assets was kr167.4 Mil.
Total Assets was kr231.2 Mil.
Property, Plant and Equipment(Net PPE) was kr11.0 Mil.
Depreciation, Depletion and Amortization(DDA) was kr9.0 Mil.
Selling, General, & Admin. Expense(SGA) was kr50.9 Mil.
Total Current Liabilities was kr30.6 Mil.
Long-Term Debt & Capital Lease Obligation was kr3.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(45.361 / 182.116) / (35.495 / 163.38)
=0.249078 / 0.217254
=1.1465

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(88.535 / 163.38) / (101.095 / 182.116)
=0.541896 / 0.555113
=0.9762

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (178.193 + 22.87) / 223.493) / (1 - (167.398 + 11.003) / 231.203)
=0.100361 / 0.228379
=0.4394

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=182.116 / 163.38
=1.1147

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.022 / (9.022 + 11.003)) / (9.044 / (9.044 + 22.87))
=0.450537 / 0.283387
=1.5898

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(53.591 / 182.116) / (50.879 / 163.38)
=0.294268 / 0.311415
=0.9449

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((16.809 + 23.986) / 223.493) / ((3.154 + 30.594) / 231.203)
=0.182534 / 0.145967
=1.2505

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.407 - 0 - 19.279) / 223.493
=-0.123879

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Gentian Diagnostics AS has a M-score of -3.07 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.07 mean?
Gentian Diagnostics AS (OSTO:GENTOO) has a Beneish M-Score of -3.07 as of Aug. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #153 out of 767 companies in the Medical Devices & Instruments industry, placing it in the top 19.9%.
Is Gentian Diagnostics AS's Beneish M-Score too high?
Gentian Diagnostics AS's current Beneish M-Score is -3.07. Based on the distribution chart, Gentian Diagnostics AS ranks #153 out of 767 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #153 out of 767 companies for Beneish M-Score. This places Gentian Diagnostics AS in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Beneish M-Score is -3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSTO:GENTOO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr53.59, compared to a current price of kr40.00 — trading 25.4% below its estimated fair value. The current Beneish M-Score is -3.07. Gentian Diagnostics AS's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Gentian Diagnostics AS (OSTO:GENTOO), the current Beneish M-Score is -3.07 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSTO:GENTOO) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr40.00 is trading 25.4% below its estimated GF Value™ of kr53.59. GuruFocus considers Gentian Diagnostics AS to be Modestly Undervalued.

Key valuation signals for OSTO:GENTOO:

  • Beneish M-Score: -3.07
  • GF Value™: kr53.59 vs. price of kr40.00 (25.4% below fair value)
  • GF Score™: 60/100

No single metric tells the full story. See the OSTO:GENTOO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENT:Norway6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
60GF Score

Get the complete analysis for OSTO:GENTOO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.00
Price
kr53.59
GF Value